© The Canadian Journal of Urology™; 19(Supplement 1); October 2012
3.
BarryMJ, Fowler FJ, O’LearyMP et al. TheAmerican Urological
Association symptom index for benign prostatic hyperplasia.
The Measurement Committee of the American Urological
Association.
J Urol
1992;148(5):1549-1557;
discussion 1564.
4.
Kaplan SA, RoehrbornCG, Rovner ES, CarlssonM, BavendamT,
Guan Z. Tolterodine and tamsulosin for treatment of men
with lower urinary tract symptoms and overactive bladder:
a randomized controlled trial.
JAMA
2006;296(19):2319-2328.
5.
Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum
prostate-specific antigen as a predictor of prostate volume in
men with benign prostatic hyperplasia.
Urology
1999;5(3)3:
581-589.
6.
Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of
clinical trials of Permixon in the treatment of symptomatic
benign prostatic hyperplasia.
Urology
2000;55(4):533-539.
7.
Bent S, Kane C, Shinohara K et al. Saw palmetto for benign
prostatic hyperplasia.
N Engl J Med
2006;354(6):557-566.
8.
MacDonald R, Wilt TJ, Howe RW. Doxazosin for treating lower
urinary tract symptoms compatible with benign prostatic
obstruction: a systematic review of efficacy and adverse effects.
BJU Int
2004;94(9):1263-1270.
9.
MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary
tract symptoms compatible with benign prostatic hyperplasia:
Asystematic reviewof efficacy and adverse effects.
Urology
2005;
66(4):780-788.
10.
Milani S, Djavan B. Lower urinary tract symptoms suggestive
of benign prostatic hyperplasia: latest update on alpha-
adrenoceptor antagonists.
BJU Int
2005;95(
Suppl 4):29-36.
11.
Djavan B, Marberger M. A meta-analysis on the efficacy and
tolerability of
α
1
-
adrenoceptor antagonists in patients with
lower urinary tract symptoms suggestive of benign prostatic
obstruction.
Eur Urol
1999;36(1):1-13.
12.
Kaplan S, McConnell J, Roehrborn C et al. Combination therapy
with doxazosin and finasteride for benign prostatic hyperplasia
in patients with lower urinary tract symptoms and a baseline
totalprostatevolumeof25mLorgreater.
JUrol
2006;175(1):217-220;
discussion 220-221.
13.
Kazuki K, Masaki Y, Yukio H for the Silodosin Clinical Study
Group. Silodosin, a new alpha 1a-adrenoceptor selective
antagonist for treating benign prostatic hyperplasia: results of
a phase III randomized, placebo-controlled, double-blind study
in Japanese men.
BJU Int
2006;98(5):1019-1024.
14.
Montorsi F. Profile of silodosin.
Eur Urol
2010;9(
Suppl):491-495.
Corrigendum.
Eur Urol
2011;59(2):315.
15.
Morganroth J, Lepor H, Hill LA, Volinn W, Hoel G. Effects
of the selective a1A-adrenoceptor antagonist silodosin on
ECGs of healthy men in a randomized, double blind, placebo-
moxifloxacin-controlled study.
Clin Pharmacol Ther
2010;87(5):
609-613.
16.
Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E,
Fernandez E: European Silodosin Study Group. Silodosin
therapy for lower urinary tract symptoms inmenwith suspected
benign prostatic hyperplasia: results of an international,
randomized, double-blind, placebo- and active-controlled
clinical trial performed in Europe.
Eur Urol
2011;59(3):
342-352.
17.
Yu HJ, Lin AT, Yang SS et al. Non-inferiority of silodosin to
tamsulosinintreatingpatientswithlowerurinarytractsymptoms
(
LUTS) associated with benign prostatic hyperplasia (BPH).
BJU Int
2011;108(11):1843-1848.
18.
Miyakita H, Yokoyama E, Onodera Y et al. Short-term
effects of crossover treatment with silodosin and tamsulosin
hydrochloride for lower urinary tract symptoms associated
with benign prostatic hyperplasia.
Int J Urol
2010;17(10):
869-875.
19.
Yukio H, Kazuki K, Masayuki T, Masaki Y. Ejaculation disorder
is associated with increased efficacy of silodosin for benign
prostatic hyperplasia.
Urology
2010;76(6):1446-1450.
Kapoor
16
20.
Nickel JC, O’Leary MP, Lepor H et al. Silodosin for men with
chronic prostatitis/chronic pelvic pain syndrome: results of a
phase II multicenter, double-blind, placebo controlled study.
J Urol
2011;186(1):125-131.
21.
Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G;
ARIA3001 ARIA 3002 and ARIA3003 Study Investigators.
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types
1
and 2 (dutasteride) in men with benign prostatic hyperplasia.
Urology
2002;60(3):434-441.
22.
Steers WD. 5 alpha-reductase activity in the prostate.
Urology
2001;58(6
Suppl 1):17-24:discussion 24.
23.
Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and
the concept of 5alpha-reductase inhibition in human benign
prostatic hyperplasia.
Eur Urol
2000;37(4):367-380.
24.
Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB,
Hobbs S. Marked suppression of dihydrotestosterone in
menwithbenignprostatichyperplasiabydutasteride,adual5alpha-
reductase inhibitor.
J Clin Endocrinol Metab
2004;89(5):2179-2184.
25.
Gormley GJ, Stoner E, Bruskewitz RC et al. The effect of
finasteride in men with benign prostatic hyperplasia.
N Engl J
Med
1992;327(17):1185-1191.
26.
Health Canada. Finasteride (Proscar, Propecia) and dutasteride
(
Avodart, Jalyn): may increase the risk of high grade prostate
cancer. 2012 March:
/
advisories-avis/_2012/2012_38-eng.php.
27.
Roehrborn CG, Nickel JC, Andriole GL et al. Dutasteride
improves outcomes of benign prostatic hyperplasia when
evaluated for prostate cancer risk reduction: secondary analysis
of the REduction by DUtasteride of prostate Cancer Events
(
REDUCE) trial.
Urology
2011:78(3):641-646.
28.
McConnell JD, Roehrborn CG, Bautista OM et al; Medical
Therapy of Prostatic Symptoms (MTOPS) Research Group.
The long-term effect of doxazosin, finasteride, and combination
therapy on the clinical progression of benign prostatic
hyperplasia.
N Engl J Med
2003:349(25):2387-2398.
29.
Roehrborn CG, Siami P, Barkin J et al; CombATStudyGroup.
The influence of baseline parameters on changes in international
prostate symptom score with dutasteride, tamsulosin, and
combination therapy among men with symptomatic benign
prostatic hyperplasia and an enlarged prostate: 2-year data
from the CombAT study.
Eur Urol
2009;55(2):461-471.
30.
Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms
and male sexual dysfunction: the multinacional Surrey of the
aging male (MSAM-7).
Eur Urol
2003;44(6):637-649.
31.
McVary KT, McKenna KE. The relationship between erectile
dysfunction and lower urinary tract symptoms: Epidemiological,
clinical, andbasic science evidence.
CurrUrol Rep
2004;5(4):251-257.
32.
Gacci M, Eardley I, Giuliano F et al. Critical analysis of the
relationship between sexual dysfunctions and lower urinary
tract symptoms due to benign prostatic hyperplasia.
Eur Urol
2011;60(4):809-825.
33.
Andersson KE, de Groat WC, McVary KT et al. Tadalafil for the
treatment of lower urinary tract symptoms secondary to benign
prostatic hyperplasia: pathophysiology and mechanism(s) of
action.
Neurourol Urodyn
2011;30(3):292-301.
34.
McVaryKT, RoehrbornCG, Kaminetsky JCet al. Tadalafil relieves
lower urinary tract symptoms secondary to benign prostatic
hyperplasia.
J Urol
2007;177(4):1401-1407.
35.
McVaryKT,MonnigW, Camps JLJr, Young JM, TsengLJ, Vanden
Ende G. Sildenafil citrate improves erectile function and urinary
symptoms in men with erectile dysfunction and lower urinary
tract symptoms associated with benign prostatic hyperplasia:
a randomized, double-blind trial.
J Urol
2007;177(3):1071-1077.
36.
Stief CG, Porst H, Neuser D, BenekeM, Ulbrich E. Arandomized,
placebo-controlled study to assess the efficacy of twice-daily
vardenafil in the treatment of lower urinary tract symptoms
secondary to benign prostatic hyperplasia.
Eur Urol
2008;53(6):
1236-1244.
